<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing recommendations for antiviral agents for the treatment of influenza in children and adolescents&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing recommendations for antiviral agents for the treatment of influenza in children and adolescents<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing recommendations for antiviral agents for the treatment of influenza in children and adolescents<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug/formulation</td> <td class="subtitle1" colspan="4">Dosing recommendations</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Oseltamivir (Tamiflu)*</td> </tr> <tr> <td class="indent1" rowspan="6"> <ul> <li>30 mg capsule</li> <li>45 mg capsule</li> <li>75 mg capsule</li> <li> 6 mg/mL suspension<sup>¶</sup></li> </ul> </td> <td colspan="4"><strong>1 through 12 years</strong></td> </tr> <tr> <td class="indent1" colspan="4">Children ≥12 months should receive approximately 4 mg/kg per day orally divided into 2 doses for a 5-day treatment course</td> </tr> <tr> <td class="indent1"><strong>≤15 kg</strong></td> <td><strong>&gt;15 to 23 kg</strong></td> <td><strong>&gt;23 to 40 kg</strong></td> <td><strong>&gt;40 kg</strong></td> </tr> <tr> <td class="indent2">60 mg/day orally divided into 2 doses for 5 days</td> <td>90 mg/day orally divided into 2 doses for 5 days</td> <td>120 mg/day orally divided into 2 doses for 5 days</td> <td>150 mg/day orally divided into 2 doses for 5 days</td> </tr> <tr> <td colspan="4"><strong>≥13 years</strong></td> </tr> <tr> <td class="indent1" colspan="4">150 mg/day orally divided into 2 doses for 5 days</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Baloxavir (Xofluza)<sup>Δ</sup></td> </tr> <tr> <td class="indent1" rowspan="2"> <ul> <li>40 mg tablet</li> <li> 80 mg tablet</li> <li>2 mg/mL oral suspension</li> </ul> </td> <td colspan="4"><strong>≥5 years</strong></td> </tr> <tr> <td class="indent1" colspan="4"> <ul> <li>Weight &lt;20 kg (oral suspension) – 2 mg/kg orally as a single dose</li> <li>Weight 20 to &lt;80 kg (oral suspension or tablet) – 40 mg orally as a single dose</li> <li>Weight ≥80 kg (oral suspension or tablet) – 80 mg orally as a single dose</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="5">Peramivir (Rapivab)*</td> </tr> <tr> <td class="indent1" rowspan="4"> <ul> <li>200 mg in 20 mL (10 mg/mL) in a single-use vial</li> </ul> </td> <td colspan="4"><strong>6 months through 12 years</strong></td> </tr> <tr> <td class="indent1" colspan="4">12 mg/kg per dose IV as a single dose (maximum dose 600 mg)</td> </tr> <tr> <td colspan="4"><strong>≥13 years</strong></td> </tr> <tr> <td class="indent1" colspan="4">600 mg IV as a single dose</td> </tr> <tr> <td class="subtitle2_left" colspan="5">Zanamivir (Relenza)<sup>◊</sup></td> </tr> <tr> <td class="indent1" rowspan="2"> <ul> <li>5 mg per inhalation (Diskhaler)</li> </ul> </td> <td colspan="4"><strong>≥7 years</strong></td> </tr> <tr> <td class="indent1" colspan="4">2 inhalations (10 mg total per dose) twice daily for 5 days<sup>§</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is meant for use with UpToDate content related to treatment of seasonal influenza in children. The choice of agent for treatment may vary with the age of the child and susceptibility patterns of circulating strains. Refer to UpToDate content for additional details, including indications for treatment and dosing recommendations for oseltamivir in infants younger than 1 year.</div><div class="graphic_footnotes"><p>IV: intravenously.</p>
<p>* Dose adjustment is necessary for patients with renal insufficiency.</p>
<p>¶ When dispensing the oral suspension of oseltamivir, providers and pharmacists must take care to provide a dosing device that matches the units of measure on the prescription.</p>
<p>Δ Baloxavir is available in Japan for the treatment of influenza in children &lt;12 years of age who weigh at least 10 kg. Refer to Japanese prescribing information for dosing information for children &lt;12 years of age.</p>
<p>◊ Zanamivir is not recommended for the treatment of hospitalized patients, because of limited data in patients with severe influenza. Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators.</p>
§ Two doses should be administered on day 1, provided that the doses can be spaced at least 2 hours apart.</div><div class="graphic_reference">References:
<ol>
<li>American Academy of Pediatrics. Non-HIV antiviral Drugs. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32<sup>nd</sup> ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.930.</li>
<li>Rapivab (peramivir injection) for intravenous use. US Food &amp; Drug Administration (FDA) approved product information. Revised January 2021. US Food &amp; Drug Administration. Available at: <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" target="_blank">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a> (Accessed on February 3, 2021).</li>
<li>Xofluza (baloxavir marboxil) prescribing information. US Food and Drug Administration (FDA) approved product information. Revised August 2022. Available online at: <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</a> (Accessed on August 16, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 70571 Version 25.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
